TRU

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated:

12/14/06

Signature

(Ginny Blundell)

Docket No.: PROL-P01-024

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of:

agneni et al.

Application No.: 10/547,845

Confirmation No.: 9728

Filed: March 2, 2004

Art Unit: N/A

For:

POSH INTERACTING PROTEINS AND

RELATED METHODS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited in a Supplementary Partial European Search Report issued September 15, 2006, during the prosecution of European Application No. EP 04 71 6503, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Supplementary Partial European Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists.

Application No.: 10/547,845 Docket No.: PROL-P01-024

Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. PROL-P01-024.

Dated: December 14, 2006

Respectfully submitted,

Anita Varma

Registration No.: 43,221

FISH & NEAVE IP GROUP, ROPES & GRAY

LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08A/B (07-06)

APPROVED FOR USE THROUGH 09/30/2006. OMB 0651-0031
U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE NDER THE PAPERWORK REDUCTION ACT OF 1995, NO PERSONS ARE REQUIRED TO RESPOND TO A COLLECTION OF INFORMATION UNLESS IT CONTAINS A VALID OMB CONTROL NUMBER.

SUBSTITUTE FOR FORM 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(USE AS MANY SHEETS AS NECESSARY)

SHEET OF 1

WATAINS A VALID OMB WATROE NOMBER.				
COMPLETE IF KNOWN				
APPLICATION NUMBER	10/547,845			
FILING DATE	MARCH 2, 2004			
FIRST NAMED	DANIEL N. TAGLICHT			
ART UNIT	N/A			
EXAMINER NAME	NOT YET ASSIGNED			
ATTORNEY DOCKET NUMBER	PROL-P01-024			

U.S. PATENT DOCUMENTS					
EXAMINER INITIALS*	CIT E NO.1	DOCUMENT NUMBER NUMBER-KIND CODE ² (<i>IF</i> KNOWN)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

	FOREIGN PATENT DOCUMENTS					
EXAMINER INITIALS*	CIT E NO.1	FOREIGN PATENT DOCUMENT COUNTRY CODE ³ -NUMBER ⁴ -KIND CODE ⁵ (IF KNOWN)	PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	⊺ ⁵

*EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. * CITE NO.: THOSE APPLICATION(S) WHICH ARE MARKED WITH AN SINGLE ASTERISK (*) NEXT TO THE CITE NO. ARE NOT SUPPLIED (UNDER 37 CFR 1.98(A)(2)(III)) BECAUSE THAT APPLICATION WAS FILED AFTER JUNE 30, 2003 OR IS AVAILABLE IN THE IFW. 'APPLICANTS UNIQUE CITATION DESIGNATION NUMBER (OPTIONAL). * SEE KINDS CODES OF USPTO PATENT DOCUMENTS AT WWW.USPTO.GOV. OR MPEP 901.04. * SENTING OF THE THAT ISSUED THE DOCUMENT, BY THE TWO-LETTER CODE (WIPO STANDARD ST.3). * FOR JAPANESE PATENT DOCUMENTS, THE INDICATION OF THE YEAR OF THE REIGN OF THE EMPEROR MUST PRECEDE THE SERIAL NUMBER OF THE PATENT DOCUMENT. * KIND OF DOCUMENT BY THE APPROPRIATE SYMBOLS AS INDICATED ON THE DOCUMENT WIPO STANDARD ST.16 IF POSSIBLE. * APPLICANT IS TO PLACE A CHECK MARK HERE IF ENGLISH LANGUAGE TRANSI ATION IS ATTACHED. PLACE A CHECK MARK HERE IF ENGLISH LANGUAGE TRANSLATION IS ATTACHED.

NON PATENT LITERATURE DOCUMENTS				
EXAMIN ER INITIALS	CITE NO.1	INCLUDE NAME OF THE AUTHOR (IN CAPITAL LETTERS), TITLE OF THE ARTICLE (WHEN APPROPRIATE), TITLE OF THE ITEM (BOOK, MAGAZINE, JOURNAL, SERIAL, SYMPOSIUM, CATALOG, ETC.), DATE, PAGE(S), VOLUME-ISSUE NUMBER(S), PUBLISHER, CITY AND/OR COUNTRY WHERE PUBLISHED.	T²	
	CA	ACHTERBERG, V., "POSH 4, A NOVEL PUTATIVE TRANSCRIPTION FACTOR, INTERACTS WITH A SPECIFIC HUMAN SPROUTY 4 ISOFORM", BLOOD, VOL. 98(11), PART 1, PAGE 823A (2001)		
	СВ	ETTENBERG ET AL., "CBL-B-DEPENDENT COORDINATED DEGRADATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR SIGNALING COMPLEX", THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 276(29) PP. 27677-27684 (2001)		
	CC	JISHAGE ET AL., "IDENTIFICATION OF TARGET GENES FOR EWS/ATF-1 CHIMERIC TRANSCRIPTION FACTOR", ONCOGENE, VOL. 22(1); 41-49 (2003)		
	CD	KEANE ET AL., "CBL-3: A NEW MAMMALIAN CBL FAMILY PROTEIN", ONCOGENE, VOL. 18(22) PP. 3365-3375 (1999)		
	CE	SMIT, L. AND BORST, J., "THE CBL FAMILY OF SIGNAL TRANSDUCTION MOLECULES", CRITICAL REVIEWS IN ONCOGENESIS, VOL. 8(4) PP. 359-379 (1997)		

*EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

'APPLICANT'S UNIQUE CITATION DESIGNATION NUMBER (OPTIONAL). ²APPLICANT IS TO PLACE A CHECK MARK HERE IF ENGLISH LANGUAGE TRANSLATION IS ATTACHED.

EXAMINE	DATE
R	CONSIDERED

PTO/SB/92 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(pplication No. (if known): 10/547,845

Attorney Docket No.: PROL-P01-024

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	December 14, 2006			
	Date			
		/		
		(\cdot, \cdot)		
		MILLEY		
		Signature (
		Ginny Blundell		
Typed or printed name of person signing Certificate				
		(617) 951-7000		
Regi	stration Number, if applicable	Telephone Number		

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS by Applicant (5 References) (1 page)

References (5, CA-CE)

Copy of Supplementary Partial European Search Report (3 pages)